Sub-stoichiometric degradation is dispensable for potent PROTACs as demonstrated by irreversible covalent BTK degraders

Baylor College of Medicine, The Ohio State University Comprehensive Cancer Center
https://doi.org/10.1038/s41467-026-78239-9

The ability of PROTACs to act catalytically and degrade multiple proteins is reported to be key to their efficacy. This has led to the theory that PROTACs using an irreversible covalent ligand to target the protein of interest would not be effective, as they can't operate via this mechanism.

To investigate this theory, the authors studied PROTACs against Bruton's tyrosine kinase (BTK). They did this using poseltinib, whose binding to BTK is dependent on covalent bond formation, as opposed to ibrutinib-based ligands, which display significant non-covalent binding. PROTACs based on poseltinib effectively and rapidly degraded BTK, showing this can be achieved without catalytic turnover of the PROTAC itself. They also propose a new model, termed E3-catalysis, in which degradation is catalytic with respect to the E3 ligase, validating covalent PROTACs as a viable strategy. Their modelling suggests that for covalent PROTACs, high affinity for the E3 ligase can cause a strong hook effect and be detrimental to efficacy.

How Many Crystal Structures Do You Need to Trust Your Docking Results?

Memorial Sloan Kettering Cancer Center, Open Molecular Software Foundation, Diamond Light Source Ltd
https://doi.org/10.1021/acs.jmedchem.5c03559

Structure-based drug design (SBDD) is a key concept which can be used from hit ID to lead optimisation campaigns. During H2L and lead optimisation, it is common to continue generating new crystal structures as the molecules become more advanced, with the hope that it leads to more accurate docking predictions. However, this can add a significant time and cost burden to the project.

In this article, the authors tested this hypothesis with a retrospective analysis of the COVID Moonshot project on the SARS-CoV-2 main protease. This gave them access to crystal structures from across a full drug discovery programme as the molecules became more complex. They demonstrated a diminishing returns effect after ~5 crystal structures per generic Bemis-Murcko scaffold. However, they note that for targets which undergo significant rearrangement upon ligand binding, more structures will likely be needed.

Proteome-guided drug discovery maps and mitigates therapeutic degrader toxicity

AstraZeneca, The Francis Crick Institute, Charité Universitätsmedizin
https://doi.org/10.1038/s41589-026-02347-2

PROTACs offer a unique way to drug challenging targets by degrading them rather than inhibiting them. However, this also raises safety concerns related to off-target degradation potentially leading to toxicity and limiting their use.

In this work, the authors developed a high-throughput proteomics framework to identify and mitigate liver toxicity mechanisms of androgen receptor (AR) PROTACs. They did this by using an AR-negative cell line, where changes to the proteome are expected to result from off-target effects.

They found that several AR-PROTACs based on CRBN inhibit electron transport chain complex I as a primary toxicity mechanism. They were then able to identify molecules with minor modifications to the CRBN-binder and linker region, which did not carry this liability. These compounds retained AR degradation and showed improved efficacy over enzalutamide in a castration-resistant prostate cancer xenograft model.

FDA Approvals

An oral HSV helicase–primase inhibitor approved for refractory mucocutaneous HSV in immunocompromised adults, and the first new anti-HSV mechanism approved in nearly 30 years, retaining activity against nucleoside-analogue-resistant strains.

An oral small-molecule inhibitor of the menin–KMT2A (MLL) protein–protein interaction, granted Breakthrough Therapy designation in relapsed/refractory KMT2A-rearranged acute leukaemia, with early data showing little interaction with azole antifungals.

An oral deoxycytidine kinase (dCK) inhibitor granted Fast Track with KRAS G12C inhibitors in previously treated G12C-mutant NSCLC, blocking the nucleoside salvage pathway that KRAS-inhibited tumours appear to rely on more heavily.

Forwarded this email?